Week after week this board idiots are so "sure" of so called buyout
You're overlooking several fundamental points. There are no other $B opportunities that Phama
can go after, and PFE, MRK AZN have had major revenue losses due to patent cliffs. Aside from
a combo pill (Statin and Vascepa) all of the above would be very motivated to aquire AMRN. This
can't happen until a proper valuation can be determined, and that can't occur until a decision is
made on the NCE. I just happen to be in Industry, and can suggest that interest level is high. I am
not involved with any of the above mentioned companies.